Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 70, Issue 3, Pages 489-+Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2013.10.049
Keywords
5-alpha reductase; 5-alpha reductase inhibitors; androgenetic alopecia; dutasteride; finasteride; male pattern baldness; male pattern hair loss; treatment
Categories
Funding
- GlaxoSmithKline
Ask authors/readers for more resources
Background: Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment. Objective: We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha reductase inhibitor) and placebo in men with androgenetic alopecia. Methods: Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes. Results: In total, 917 men were randomized. Hair count and width increased dose dependently with dutasteride. Dutasteride 0.5 mg significantly increased hair count and width in a 2.54-cm diameter and improved hair growth (frontal view; panel photographic assessment) at week 24 compared with finasteride (P = .003, P = .004, and P = .002, respectively) and placebo (all P < .001). The number and severity of adverse events were similar among treatment groups. Limitations: The study was limited to 24 weeks. Conclusions: Dutasteride increased hair growth and restoration in men with androgenetic alopecia and was relatively well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available